L
Liberty Dialysis
Chronic kidney disease outreach and home dialysis programs
About Liberty Dialysis
Liberty Dialysis, LLC functioned as a key operator and developer of dialysis clinics across the United States, carving out a specific niche by establishing facilities in underserved communities. The company was founded in 2002 by Mark Caputo, who drew upon his extensive experience in the healthcare sector to guide its growth. His academic background, which includes an M.B.A. from Harvard Business School and a B.A. in Economics from Princeton University, provided a strong foundation for the company's strategic direction.
The firm’s business model centered on creating strategic joint ventures with local nephrologists and non-profit hospital systems. This partnership-based approach allowed Liberty Dialysis to expand its footprint while ensuring that clinical policies were dictated by local medical directors rather than corporate business managers. Before its acquisition, the company had grown to operate over 260 clinics, serving approximately 20,000 patients, making it one of the largest dialysis providers globally. The company generated revenue by providing dialysis services to patients with End-Stage Renal Disease (ESRD).
A significant milestone in the company's history occurred in 2012 when it was acquired by Fresenius Medical Care, the world's largest provider of dialysis products and services. The acquisition, valued at approximately $1.7 billion, integrated Liberty Dialysis into Fresenius's extensive network. Following the merger, Mark Caputo took on the role of Managing Partner of Joint Ventures for Fresenius Medical Care, continuing his focus on partnership-driven healthcare models. The transaction required Fresenius to divest some clinics to comply with antitrust regulations, a move overseen by the Federal Trade Commission to preserve market competition.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2010 | $0 | — | Renal Advantage | — |
| LATE VCOther financing | Jul 2010 | $35M | $140M | Norwest Mezzanine Partners | — |
Growth signals
Latest recorded traffic for Liberty Dialysis is 0 monthly website visits, down 100% over the last three months. Liberty Dialysis's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Liberty Dialysis in the Mercer Island ecosystem
The Liberty Dialysis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series B and later2 investors entered at this stage
InvestMichigan- NPNorwest Mezzanine Partners
Other known investors1 additional known investor
- RARenal Advantage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Liberty Dialysis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Liberty Dialysis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










